Has Carolyn Greer received payments from drug or device companies?

Yes. Drug and device makers reported $23,443 in general payments to Carolyn Greer across 89 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Carolyn Greer did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Carolyn Greer come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Carolyn Greer

Addiction Medicine · Fort Wayne, INNPI 1568458990

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $20,345 of the $23,443 with a category attached, or 86.8%. Pear Therapeutics (US), Inc. accounts for 87.0% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2022 at $19,714 and has fallen 97.7% since, to $453 in 2025. Among addiction medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$23,443in general payments, 2019–2025

Across 89 payments — averaging $263.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pear Therapeutics (US), Inc.$20K
AbbVie$797
Axsome Therapeutics, Inc.$517
Otsuka America Pharmaceutical, Inc.$341
Idorsia Pharmaceuticals US Inc$243
Lilly USA, LLC$238
plus $902 from 15 others

What the payments were for

Consulting fees$20,34587%
Food & beverage$3,09813%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pear Therapeutics (US), Inc.	15	$20,406
AbbVie	15	$797
Axsome Therapeutics, Inc.	9	$517
Otsuka America Pharmaceutical, Inc.	9	$341
Idorsia Pharmaceuticals US Inc	2	$243
Lilly USA, LLC	2	$238
Corium, LLC	5	$151
Eisai Inc.	2	$144
Teva Pharmaceuticals USA, Inc.	2	$136
Sunovion Pharmaceuticals Inc.	7	$103
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	4	$64
Merck	3	$46
Takeda Pharmaceuticals U.S.A., Inc.	2	$40
Indivior Inc.	2	$40
E.r. Squibb & Sons, L.L.C.	2	$34
Lundbeck LLC	2	$34
Alkermes, Inc.	2	$28
Neurocrine Biosciences, Inc.	1	$23
Biogen	1	$23
Gilead	1	$22
Ironshore Pharmaceuticals Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

RESET-O$3,325
VRAYLAR$597
Auvelity$457
QUVIVIQ$243
Dayvigo$124
AUSTEDO$122
UBRELVY$122
MOUNJARO$121
Azstarys$121
ZEPBOUND$116
REXULTI$109

How this compares

$23,443 in reported general payments places this provider in the 95th percentile of 30 addiction medicine providers in Indiana.

See all addiction medicine providers in Indiana →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl	240	$25,236
TrintellixVortioxetine Hydrobromide	22	$10,595
SuboxoneBuprenorphine Hcl/Naloxone Hcl	15	$3,433
Lisdexamfetamine Dimesylate	17	$2,622
Venlafaxine Hcl ErVenlafaxine Hcl	14	$1,913
Divalproex Sodium ErDivalproex Sodium	18	$1,137
Buspirone Hcl	55	$1,005
Aripiprazole	12	$952
Amitriptyline Hcl	34	$494
Gabapentin	55	$454
Bupropion XlBupropion Hcl	44	$427
Hydroxyzine Hcl	35	$418
Mirtazapine	38	$345
Prazosin Hcl	24	$276
Trazodone Hcl	45	$260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix	$40	$10,59522 claims
Indivior Inc.Suboxone	$40	$3,43315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 addiction medicine providers in Indiana.

Other addiction medicine in Fort Wayne

Timothy KowaleskiFort Wayne$15K
Zeenat HabibullahFort Wayne$158
Faryal KhanFort Wayne$49
Timothy KellyIndianapolis$15K
Michael MitcheffIndianapolis$11K
Pamela HansonLawrenceburg$508
Patricia Miller-CanfieldBloomfield$469
Khaleelur ZackariyaMishiwaka$437
Peter FarrFishers$341
Claudie JimenezAlexandria$202

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →